Radiopharmaceutical Market Monopolization
Cardinal Health paid $26.8 million to settle charges that it illegally monopolized 25 local markets for the sale and distribution of low-energy radiopharmaceuticals and forced hospitals and clinics to pay inflated prices for these drugs. The Federal Trade Commission (FTC) alleged that in 2003 and 2004, Cardinal employed anticompetitive tactics to become the largest operator of radiopharmacies in the U.S. and the sole radiopharmacy operator in 25 metropolitan areas. As a result, the FTC alleged that Cardinal obtained de facto exclusive distribution rights to the only heart perfusion agents (HPAs) available on the market and prevented potential entrants from gaining market access.
- Misconduct Type
- Enforcement Agency
- Contracting Party
- Court Type
- Date of Settlement Announcement
|Cardinal Health, Inc.||$26,800,000|